Cambridge biotech Oncorus Inc. said Wednesday that it raised $79.5 million from new and existing investors to develop a new cancer treatment. Oncorus said this second round of funding for the startup was led by New-York based investment firms Cowen Healthcare Investments and Perceptive Advisors, along with investors from the previous round of financing including Cambridge-based MPM Capital. The company plans to use the funds to bring a drug that targets solid tumors found in different types of cancers — including breast, skin, and liver cancers — to clinical trial in early 2020. “Oncolytic virus therapies have the potential to transform outcomes for cancer patients,” said Ted Ashburn, chief executive of Oncorus. Allison Hagan can be reached at [email protected] Follow her on Twitter @allisonhxgan.
- China-made cancer drug approved for US market
- Smartphones and cancer drugs rely on Chinese rare earths. What happens if Beijing limits them?
- Hope for treating 'deadliest form of cancer' as scientists find drug combination 'can shrink pancreatic tumours'
- Can you vaccinate yourself against cancer?
- Scientists discover that combining two drugs could help children fight an incurable brain cancer that usually kills in five years
- Ladies, include soy in your diet. It may be the best defence against breast cancer
- Boy, 7, whose 'growing pains' were revealed to be cancerous leg tumors that gave him 30% chance of survival dies a year after being diagnosed
- Cancer's ring-shaped DNA lets tumors evolve too fast for treatments to keep up - turning the disease chemo-resistant, scientists say
- Biden threatens funding cut if cancer trials conceal results
- Hope for thousands of prostate cancer sufferers as trial finds a 'precision' drug can help incurable patients live almost four months longer
Oncorus raises $79.5m to develop solid tumor cancer drug have 269 words, post on www.bostonglobe.com at August 21, 2019. This is cached page on Drudgereport. If you want remove this page, please contact us.